By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week. At a reputed annual cost of at least £60,000 a year, including the care bill, it […]
Dr Hoekema brings over four decades of successful biotech and life science leadership Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships Southampton, UK, 2 October 2024 – Curve […]
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]
Stockholm, Sweden, September 3, 2024 – Following the announcement by Asahi Kasei Corporation (“Asahi Kasei”) on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas” or the “Company”), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas […]
Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]
